OPRPN
Opiorphin prepropeptide
Also known as: BPLP, PRL1, PROL1, PROL1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q99935
- Gene
- OPRPN
- Ensembl
- ENSG00000171199
- Chromosome
- 4
- Canonical length
- 248 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted in other tissues
OverviewNCBI Gene
This gene encodes a member of the proline-rich protein family. The encoded protein has multiple proposed functions, including roles in pain suppression, penile erection, and protection of the eye surface. The QRFSR pentapeptide, known as opiorphin, is derived from the N-terminal of this protein. Opiorphin inhibits the enkephalin-inactivating peptidases neprilysin and aminopeptidase N, and this activity is thought to reduce sensitivity to painful stimuli by effecting enkephalin-related activation of opioid-dependent pathways. Opiorphin may also act as an anti-depressant. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2014]
Canonical amino-acid sequenceUniProt
248 residues, UniProt reviewed canonical sequence.
>Q99935|OPRPN
1 MKLTFFLGLL ALISCFTPSE SQRFSRRPYL PGQLPPPPLY RPRWVPPSPP PPYDSRLNSP
61 LSLPFVPGRV PPSSFSRFSQ AVILSQLFPL ESIRQPRLFP GYPNLHFPLR PYYVGPIRIL
121 KPPFPPIPFF LAIYLPISNP EPQINITTAD TTITTNPPTT ATATTSTSTK PTMTISSSTV
181 PISSTPEPAT SISAATPAAS TENTTQILAN RPHTVLLNAT VQVTTSNQTI LSSPAFKSFW
241 QKLFAIFGLocalizationUniProt · AlphaFold · HPA
Whether an antibody against OPRPN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.68
- Highest tissue expression
- 145 nTPM
Expression across tissuesHPA
Tissue
- salivary gland: 145 nTPM
- breast: 28 nTPM
- epididymis: 1.4 nTPM
- liver: 0.8 nTPM
- testis: 0.3 nTPM
- skin: 0.2 nTPM
Single-cell type
- lacrimal acinar cells: 32,940 nCPM
- conjunctival goblet cells: 116 nCPM
- neutrophils: 81 nCPM
- breast secretory cells: 37 nCPM
- vascular smooth muscle cells: 26 nCPM
- salivary acinar cells: 25 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- midbrain: 0.9 nTPM
- thalamus: 0.3 nTPM
- hypothalamus: 0.1 nTPM
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.73
- gnomAD pLI
- 0.39
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads OPRPN as an antibody target. Whether an autoantibody or antibody against OPRPN could matter depends on whether native OPRPN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
OPRPN is annotated as secreted, so native OPRPN circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label OPRPN as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...